Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.73 |
| ▸ | LMNA | P02545 | 4/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | GAA | P10253 | 2/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | USP2 | O75604 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12793245 | 0.90 | POLB (0.88) | POLBLMNASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL12793258 | 0.85 | POLB (1.00) | POLBLMNASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL8871272 | 0.83 | POLB (0.76) | POLBLMNASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL28072234 | 0.83 | POLB (0.76) | POLBLMNASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL12793270 | 0.83 | POLB (0.96) | POLBLMNASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL12793250 | 0.83 | POLB (0.96) | POLBLMNASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL3373909 | 0.82 | USP2 (0.76) | POLBLMNASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL2769910 | 0.81 | POLB (0.73) | POLBLMNASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL2923158 | 0.81 | POLB (0.73) | POLBLMNASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL289534 | 0.81 | LMNA (0.82) | POLBLMNASMN1; SMN2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110312945-A1 | CRTH2 MODULATORS | IRONWOOD PHARMACEUTICALS, INC. | 2011-12-22 | — | — | US | disclosed |
| WO-2010039982-A1 | CRTH2 MODULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312945-A1 | CRTH2 MODULATORS | HRH2, HRH1, NR1H2 | POLB 4039/4885LMNA 4591/4885SMN1; SMN2 4245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.